AbCellera appoints scientist Stephen Quake to board of directors

VANCOUVER - AbCellera Biologics Inc. (NASDAQ:ABCL) announced Monday the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. The announcement comes as the company's stock has experienced significant volatility, with InvestingPro data showing a 27% decline over the past week despite an impressive 92% gain over the last six months.

Dr. Quake, the Lee Otterson Professor of Bioengineering and Professor of Applied Physics at Stanford University, brings extensive scientific credentials to the clinical-stage biotechnology company. He has been elected to four U.S. national academies and was named a Foreign Member of the Royal Society in 2025.

"He brings a distinctive combination of scientific breadth, creativity, and interdisciplinarity that resonates with AbCellera's culture and strategy," said Carl Hansen, founder and CEO of AbCellera, in a press release statement.

Quake previously served as founding co-president of the Chan Zuckerberg Biohub starting in 2016 and later as president of the Chan Zuckerberg Biohub Network and Head of Science for the Chan Zuckerberg Initiative until 2025. Under his leadership, the Biohub operated with a launch budget of approximately $600 million.

His scientific contributions span multiple fields including single molecule biophysics, microfluidics, and genomics, with over 300 publications and more than 80 patents and patent applications. As an entrepreneur, he has co-founded more than a dozen companies in microfluidics, genomics, molecular diagnostics, and therapeutics.

Concurrent with Quake's appointment, Andrew W. Lo, Ph.D., will resign from his position as independent director. Dr. Lo, who joined the board in December 2021, is a professor at MIT Sloan School of Management and co-founder of BridgeBio Pharma.

AbCellera focuses on discovering and developing antibody-based medicines in endocrinology, women's health, immunology, and oncology.

In other recent news, AbCellera Biologics reported its second-quarter 2025 revenues at $17.1 million, a significant increase from $7.3 million in the same period last year. This boost in revenue was primarily attributed to a milestone payment associated with a Trianni license. In addition to financial updates, the company has initiated a Phase 1 clinical trial for ABCL575, an investigational antibody therapy aimed at treating moderate-to-severe atopic dermatitis. The therapy features Fc-silencing and half-life extension, potentially allowing for dosing every six months. Moreover, AbCellera has appointed Sarah Noonberg, M.D., Ph.D., as its first Chief Medical Officer, bringing over 20 years of experience in leading development programs. On the analyst front, Benchmark has maintained its Hold rating on AbCellera Biologics. These developments reflect AbCellera's ongoing efforts in advancing its clinical programs and strengthening its leadership team.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.